Sanofi will acquire Bioverativ (BIVV) for $105 per share. Bioverativ spun from Biogen (BIIB) on Feb. 1, 2017. BIVV has returned 129%. Spin-Offs are 5x more likely to be acquired. Spin-Offs outperform the general market. Both this spin BIVV and BIIB are great examples of this over performance.
